Skip to main content
CSL Named One of the Best Employers in the US for Diversity
Forbes Recognizes the Global Biotechnology Leader in its Top 50 Best Employers for Diversity 2019

KING OF PRUSSIA, Pa. – January 16, 2019 – Forbes magazine has named global biotechnology leader CSL Limited as one of The Best Employers for Diversity in the United States. CSL, the fifth largest biotechnology company in the world, ranked No. 39 in the leading business magazine’s annual list of the best 500 employers for diversity. 

This achievement reflects CSL’s focus to build a workplace culture where employees have a promising future and can fulfill their career aspirations, realize their potential and be part of a purpose-driven company that focuses on saving and protecting the lives of people around the world.

In 2018, Forbes ranked CSL as one of the top 50 employers in the world and Thomson Reuters included CSL in its top 100 global Diversity and Inclusion Index.

“At CSL, people are our greatest asset,” said Elizabeth Walker, Executive Vice President and Chief Human Resources Officer. “We rely on our people’s diverse perspectives, ideas, capabilities and experiences to help us deliver on our promise to our patients and other key stakeholders. In return, our employees build promising futures in an inclusive work environment where everyone has equitable access to career opportunities, training and benefits.”

Forbes’ recognition for The Best Employers for Diversity 2019 is based on an independent survey of more than 50,000 U.S. employees working for companies employing at least 1,000 people within their U.S. operations. For the majority of the company’s score, respondents were asked open-ended questions on a series of statements surrounding the topics of age, gender equality, ethnicity, disability, LGBTQ and general diversity concerning their own employer. The rankings were aggregated using four criteria: Direct Recommendations, Indirect Recommendations, Diversity among Top Executives/Board Members and Diversity Key Performance Indicators.

Diversity and inclusion underpin CSL’s Values of patient focus, innovation, collaboration, integrity and superior performance. Diversity and inclusion have also contributed to the company’s strong business growth and performance by helping CSL to:

  • better understand and connect with patients and other stakeholders;
  • attract, develop, retain and engage talent for long-term success;
  • foster creativity and innovation; and
  • improve the quality of the company’s decision-making.

More information on the company’s commitment to diversity and inclusion can be found on its global website. For Forbes’ complete Best Employers for Diversity 2019 list, please click here.

CSL is comprised of two businesses: CSL Behring, a recognized global leader in providing lifesaving medicines for people stricken with rare and serious diseases, like hemophilia, hereditary angioedema and primary immunodeficiency, and Seqirus, the world’s second largest influenza vaccines provider. CSL employs more than 22,000 people, bringing medicines to people in more than 60 countries.

About CSL Behring

CSL Behring is a global biotherapeutics leader driven by its promise to save lives. Focused on serving patients’ needs by using the latest technologies, we develop and deliver innovative therapies that are used to treat coagulation disorders, primary immune deficiencies, hereditary angioedema, inherited respiratory disease and neurological disorders. The company’s products are also used in cardiac surgery, organ transplantation, burn treatment and to prevent hemolytic disease of the newborn.

CSL Behring operates one of the world’s largest plasma collection networks, CSL Plasma. The parent company, CSL Limited (ASX:CSL;USOTC:CSLLY), headquartered in Melbourne, Australia, employs more than 22,000 people, and delivers its life-saving therapies to people in more than 60 countries. For inspiring stories about the promise of biotechnology, visit Vita at and follow us on


Media Contact
Greg Healy

Office: 610-878-4841

Mobile: 610-906-4564


Get our latest news releases in your inbox
* Required Fields